Optimax Access’ Post

One of the posters we'll be presenting next week at the ISPOR Europe Conference will focus on #NASH and #MASH:, "The Impact of Delayed Treatment in Patients with Noncirrhotic Non-Alcoholic Steatohepatitis (NASH) with Moderate to Advanced Fibrosis."   This work highlights our expertise in modeling complex conditions like NASH, where the timing of treatment initiation can significantly impact patient outcomes. By examining the effects of delayed treatment, we’re shedding light on the critical decisions that patients, clinicians, and payers face in managing progressive liver diseases.   Our team has a strong track record in advanced modeling techniques and health economics evaluations for challenging disease areas. We’re proud to be pushing the boundaries of evidence generation for better healthcare decision-making.   If you're attending, come by to booth 620 and let’s connect! We’d love to discuss the implications of our findings and how our expertise in complex modeling could support your projects.   #HealthEconomics #ModelingExcellence #NICEsubmission #PharmaResearch #LiverDisease #HealthcareInnovation #OptimaxAccess #ISPOR #ISPOREurope2024 ISPOR—The Professional Society for Health Economics and Outcomes Research

With the Annual Meeting of the European Charcot Foundation just around the corner, we’re excited to explore together with you the sessions, chairs, and speakers who will drive the scientific discussions from November 21st to November 23rd.Session IV: Progressive MS Don’t miss Session IV at the 32nd Annual Meeting of the European Charcot Foundation, where experts discuss the latest advancements in Progressive Multiple Sclerosis (PMS).   Chaired by: Prof. Dr. Bernhard Hemmer   Key Lectures:   🔹In “The Evolving Perception of Progressive MS”,  Prof. Dr. Alan Thompson shows us how our understanding of PMS has changed over time.   🔹 Prof. Dr. Fred Lublin provides a comprehensive overview of current and emerging therapies aimed at managing PMS in his talk about “Treatment of PMS”   🔹 “Progressive MS in Observational Data: Definition & Treatment by Prof. Tomas Kalincik, explores insights from real-world data to refine the definition and treatment strategies for PMS.   🔹 Prof. Dr. Daniel Ontaneda examines the role of biomarkers in improving diagnosis and monitoring of PMS progression in “Biomarkers in Progressive MS”    This is a must-attend session for anyone focused on advancing PMS research and patient care!       This session will conclude with a live Q&A, providing an opportunity to converse with the speakers and deepen your understanding of PMS. 📅Time: Friday, November 22nd from 10:30 – 12:00 Register to secure your spot and https://lnkd.in/d2YfsCG4 💻 For those unable to attend in person, we’ve got you covered with complete digital participation for the entire three-day programme. Just select the digital option when registering. For more information, don’t hesitate to consult the ECF website: https://lnkd.in/dEEA6qMG #ECF2024 #EuropeanCharcotFoundation #MSResearch #MultipleSclerosis #MS#HybridConference #DigitalConference

With the Annual Meeting of the European Charcot Foundation just around the corner, we’re excited to explore together with you the sessions, chairs, and speakers who will drive the scientific discussions from November 21st to November 23rd.Session IV: Progressive MS   Don’t miss Session IV at the 32nd Annual Meeting of the European Charcot Foundation, where experts discuss the latest advancements in Progressive Multiple Sclerosis (PMS).   Chaired by: Prof. Dr. Bernhard Hemmer   Key Lectures:   🔹In “The Evolving Perception of Progressive MS”,  Prof. Dr. Alan Thompson shows us how our understanding of PMS has changed over time.   🔹 Prof. Dr. Fred Lublin provides a comprehensive overview of current and emerging therapies aimed at managing PMS in his talk about “Treatment of PMS”   🔹 “Progressive MS in Observational Data: Definition & Treatment by Prof. Tomas Kalincik, explores insights from real-world data to refine the definition and treatment strategies for PMS.   🔹 Prof. Dr. Daniel Ontaneda examines the role of biomarkers in improving diagnosis and monitoring of PMS progression in “Biomarkers in Progressive MS”    This is a must-attend session for anyone focused on advancing PMS research and patient care!       This session will conclude with a live Q&A, providing an opportunity to converse with the speakers and deepen your understanding of PMS.   📅Time: Friday, November 22nd from 10:30 – 12:00 Register to secure your spot and https://lnkd.in/d2YfsCG4   💻 For those unable to attend in person, we’ve got you covered with complete digital participation for the entire three-day programme. Just select the digital option when registering.   For more information, don’t hesitate to consult the ECF website: https://lnkd.in/dEEA6qMG   #ECF2024 #EuropeanCharcotFoundation #MSResearch #MultipleSclerosis #MS#HybridConference #DigitalConference

The 7th World Bronchiectasis Conference featured a pivotal discussion among leaders of bronchiectasis registries from the US, Europe, China, India, South Korea, and Australia. These registries, extensive databases with critical patient and disease information and their complementary biobanks which store biological samples, have amassed substantial data over time. Data from the European registry, EMBARC, has already been used in over 40 publications! Recognizing the potential of combined efforts, moderator Dr. Doreen Addrizzo-Harris proposed a collaborative research approach across these registries. Moderator Dr. James Chalmers echoed this sentiment, suggesting a joint publication discussion at the next conference as a tangible goal. Audience members expressed interest in accessing registry data for their own research, a request met with encouragement from Dr. Chalmers. He added that with tens of thousands of patients contributing their data, the medical community now bears the responsibility of using this resource to improve patient care. The emergence of the Bronchiectasis Care Center Network (CCN) in the United States, with a potential of 350 centers, will be a significant development in data collection. Dr PJ McShane noted that expanding beyond the current institutions and their data banks to include public hospitals will provide a more comprehensive understanding of bronchiectasis and NTM and its impact on minority populations. Access to care has been a lifelong concern of mine. From my public health background and current engagement with people all over the world who have BE and NTM, I know there are many who do not get the care they need to fight these diseases. If you have the opportunity, please join me in participating in registries and data banks. It’s very satisfying to be involved in this global effort—and hopefully in the discovery of a cure.🫁✨ COPD Foundation www.letsbecleartoday.com #bronchiectasis #ntmlung #lunghealth #PrimaryCiliaryDyskinesia #respiratoryhealth #asthma #COPD #lungdisease #medicalresearch #clinicalTrials #chronicillness #cooperation #publichealth #patientadvocacy #healthinnovation #collaboration #patientparticipation

#ISPOR2024 | Advancing healthcare research in rare diseases At the ISPOR—The Professional Society for Health Economics and Outcomes Research 2024 conference held in Barcelona last week, a poster was presented focusing on PROMs (Patient-Reported outcomes measures) in the context of rare diseases. This important study provided valuable insights into this burden of disease and its impact on patients’ daily lives. Discover the poster, named "Revealing overlooked Symptoms of Myasthenia Gravis in France: findings from patient national survey" 👉https://lnkd.in/ecYDJd-C We are honored to have contributed to this collaborative effort alongside Alexion Pharmaceuticals, Inc. and different associations such as Myasthenia Interest Group AFM-Téléthon, Association des Myasthéniques Isolés et Solidaires AMIS. A special thank you to the patients who shared their experiences, making this research possible and helping to advance understanding myasthenia gravis. At APLUSA, we leverage our market research expertise to support scientific research, helping our partners better understand public health challenges and develop patient-centric solutions. 📰 Explore APLUSA's other contributions to medical Journals and Conferences https://lnkd.in/ecMRdEBe #MyastheniaGravis #HealthcareResearch #RareDiseases #PatientInsights #ISPORBarcelona

‼️Systemic Racism ‼️Research Funding The allocation of research funding in UK is *entrenched* in #SystemicRacism. All 3 funders, namely NIHR (National Institute for Health and Care Research), UK Research and Innovation, Wellcome Trust including Medical Research Council, favoured #CysticFibrosis from 2010 to 2024, by awarding £67 million and £74 million more than for similar genetic conditions, #SickleCellDisease and #Haemophilia respectively. https://lnkd.in/exTWyQic

Join the poster session at the 2024 ISPE Annual Meeting in Berlin on August 27th from 8:00 AM – 6:00 PM for a presentation titled: "Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data," presented by AbbVie. Social determinants of health (SDOH) play a crucial role in driving health disparities and impacting clinical research participation among underserved populations. Diversity plans in cancer clinical trials are working to reduce disparities and improve representation through real-world data (RWD). Using ConcertAI’s electronic health record (EHR) database, this study focused on patients with advanced non-small cell lung cancer (aNSCLC) to assess representation based on race, ethnicity, and SDOH. The study found that patients with linked SDOH data were more likely to be non-Hispanic White, had lower levels of education, and lower individual income compared to those without linked SDOH data. These findings highlight the importance of addressing representativeness gaps in clinical trials to ensure equitable access to healthcare. Read the abstract to learn more: https://hubs.ly/Q02LyrkP0 #HealthEquity #ClinicalResearch #SDOH #RepresentationMatters #ISPE2024

I am looking forward to presentation by AbbVie, using ConcertAI's definitive RWD, at the 2024 International Society for Pharmacoepidemiology (ISPE) meeting in Berlin. Social determinants of health (SDOH) play a crucial role in driving health disparities and impacting clinical research participation among underserved populations. Diversity plans in cancer clinical trials are working to reduce disparities and improve representation through real-world data (RWD). Using ConcertAI’s electronic health record (EHR) database, this study focused on patients with advanced non-small cell lung cancer (aNSCLC) to assess representation based on race, ethnicity, and SDOH. The study found that patients with linked SDOH data were more likely to be non-Hispanic White, had lower levels of education, and lower individual income compared to those without linked SDOH data. These findings highlight the importance of addressing representativeness gaps in clinical trials to ensure equitable access to healthcare. Read the abstract to learn more: https://hubs.ly/Q02LyrkP0

📈 LiverPRO shows an 86% prognostic accuracy validated in +450,000 individuals We are happy to share that we will present our prognostic results on LiverPRO at the EASL Congress 2024. Come by our poster: “LiverPRO outperforms FIB-4 at predicting liver-related events in a cohort of 457.152 individuals” … and lets have a discussion around the benefits and need for early detection and accurate prognosis of at-risk patients. In our study, we compared the effectiveness of LiverPRO and FIB-4 in predicting liver-related events – showing an 86 % prognostic accuracy of LiverPRO. The research is based on the UK Biobank dataset with 457.152 individuals – a general UK patient population aged 40-69. Visit our poster (#FRI-045) on June 7th at the EASL Congress 2024 to explore our results in detail. Want to know more or chat about the findings? Reach out to our CSO Katrine Prier Lindvig! Co-authored by: Katrine Prier Lindvig P Lindvig, Sören Möller, Katrine H Thorhauge, Johanne K Hansen, Camilla D Hansen, Stine Johansen, Helle L Schnefeld, Mads Israelsen, Peter Andersen, Ida Villesen, Katrine T Bech, Nikolaj Torp, Aleksander Krag, Maja Thiele. Check out our other poster for EASL: https://lnkd.in/d5vke6aQ   #EASLCongress2024 #EASLposter #datadrivendiagnostics #steatoticliverdisease

One of the exciting initiatives of the GHC summits is interdisciplinary collaborations. The Comprehensive Cancer Center in the Cloud (C-4) is one such initiatives. C-4 brings together and mobilizes human and technological/digital infrastructure to address gaps in healthcare delivery, overcome inequities in care access, and accelerate patient-empowered wholistic healthcare and quality of life for individuals and communities. Participating institutions - including academic and religious organizations - will work together to train healthcare professionals on whole person approaches to addressing health disparities and building health equity. See the C-4 concept idea in nature medicine: https://rdcu.be/dNOLD